As of November 6th, 2023, the MPN Research Foundation has opened the MPN Challenge™ funding cycle. Please click here for further details on eligibility, proposal

MPN Research Foundation is pleased to share the news of the US FDA approval of momelotinib for the treatment of myelofibrosis patients with anemia whether they have

“From the outset, we recognized that outstanding care of MPN patients required not just hematologists (who would be their primary doctors) but also the participation

Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood

Dr. Ruben Mesa on his move to Wake Forest Baptist Comprehensive Cancer Center MPN patients are asking about your recent move from MD Anderson to

Just Published NUTRIENT Trial: Mediterranean Diet Intervention in MPNs The Mediterranean diet has long been associated with disease fighting anti-inflammatory benefits. In recent years, it